Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2005

01-09-2005 | Review

Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge

Authors: Karin Holweger, Carsten Bokemeyer, Hans-Peter Lipp

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2005

Login to get access

Abstract

A narrow therapeutic index is a characteristic feature of cytotoxic agents. Some of these agents are almost entirely eliminated renally in unchanged active form. As a consequence, assessment of the individual glomerular filtration rate (GFR) may help to predict the pharmacokinetic behaviour of cytotoxic agents in plasma more precisely. In addition, GFR-adapted individualization of cancer chemotherapy may have an enormous impact on the severity of side effects. Several methods are available to determine GFR or creatinine clearance (CrCl). GFR-measurement based on experimental methods with radiolabelled isotopes, contrast media or inulin helps to reflect the real situation very closely. In addition, 24-h urine collection is a convenient and feasible method to measure creatinine clearance. Finally, several mathematical equations exist to estimate GFR or CrCl based on serum creatinine and other parameters. Only a few of these equations have been developed in oncologic patients. However, some of these equations are routinely used in clinical practice, because they allow a rapid estimation of GFR. Based on the fact that clinically relevant differences have been assessed between calculated values and the real situation, mathematical calculation of GFR or CrCl does not seem to be appropriate to assess individual renal function precisely enough over a broad range of individual GFR or CrCl. Whether the measurement of low-molecular-weight proteins, such as cystatin C and ß-trace protein, may help to reflect the real situation more precisely is a matter of controversial debate.
Literature
go back to reference Alberts DS, Chen HS, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, Gross J, Moon T, Broughton A, Salmon SE (1978) Bleomycin pharmacokinetics in man I Intravenous administration. Cancer Chemother Pharmacol 1:177–181CrossRefPubMed Alberts DS, Chen HS, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, Gross J, Moon T, Broughton A, Salmon SE (1978) Bleomycin pharmacokinetics in man I Intravenous administration. Cancer Chemother Pharmacol 1:177–181CrossRefPubMed
go back to reference American National Kidney Foundation (2002) Guideline 4 Estimation of GFR. K/DOQI Clinical practice guidelines for chronic kidney diseasae: evaluation, classification and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease American National Kidney Foundation (2002) Guideline 4 Estimation of GFR. K/DOQI Clinical practice guidelines for chronic kidney diseasae: evaluation, classification and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease
go back to reference Bjornsson TD (1979) Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 4:200–222PubMedCrossRef Bjornsson TD (1979) Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet 4:200–222PubMedCrossRef
go back to reference Bokemeyer C, Lipp HP (1997) Is there a need for pharmacokinetically guided carboplatin dose schedules? Onkologie 20:343–345CrossRef Bokemeyer C, Lipp HP (1997) Is there a need for pharmacokinetically guided carboplatin dose schedules? Onkologie 20:343–345CrossRef
go back to reference Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J (1998) Cystatin C—a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 101:875–881CrossRefPubMed Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J (1998) Cystatin C—a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 101:875–881CrossRefPubMed
go back to reference Breithaupt H, Kuenzlen E (1982) Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 66:1733–1741PubMed Breithaupt H, Kuenzlen E (1982) Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep 66:1733–1741PubMed
go back to reference Buclin T, Pechere-Bertschi A, Sechaud R, Decosterd LA, Munafo A, Burnier M, Biollaz J (1997) Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol 37:679–692PubMed Buclin T, Pechere-Bertschi A, Sechaud R, Decosterd LA, Munafo A, Burnier M, Biollaz J (1997) Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol 37:679–692PubMed
go back to reference Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J (1998) Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail 20:267–276PubMed Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J (1998) Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail 20:267–276PubMed
go back to reference Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147CrossRefPubMed Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147CrossRefPubMed
go back to reference Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed
go back to reference Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575CrossRefPubMed Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575CrossRefPubMed
go back to reference Chandra R, Barron JL (2002) Anaphylactic reaction to intravenous sinistrin (Inutest). Ann Clin Biochem 39:76CrossRefPubMed Chandra R, Barron JL (2002) Anaphylactic reaction to intravenous sinistrin (Inutest). Ann Clin Biochem 39:76CrossRefPubMed
go back to reference Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci 37:169–180PubMed Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci 37:169–180PubMed
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
go back to reference Davis GA, Chandler MH (1996) Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 53:1028–1032PubMed Davis GA, Chandler MH (1996) Comparison of creatinine clearance estimation methods in patients with trauma. Am J Health Syst Pharm 53:1028–1032PubMed
go back to reference Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226CrossRefPubMed Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226CrossRefPubMed
go back to reference Du BD, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known 1916. Nutrition 5:303–311PubMed Du BD, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known 1916. Nutrition 5:303–311PubMed
go back to reference Edwards KD, Whyte HM (1959) Plasma creatinine level and creatinine clearance as tests of renal function. Australas Ann Med 8:218–224PubMed Edwards KD, Whyte HM (1959) Plasma creatinine level and creatinine clearance as tests of renal function. Australas Ann Med 8:218–224PubMed
go back to reference Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432–5438PubMed Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432–5438PubMed
go back to reference Fawdry RM, Gruenewald SM, Collins LT, Roberts AJ (1985) Comparative assessment of techniques for estimation of glomerular filtration rate with 99mTc-DTPA. Eur J Nucl Med 11:7–12CrossRefPubMed Fawdry RM, Gruenewald SM, Collins LT, Roberts AJ (1985) Comparative assessment of techniques for estimation of glomerular filtration rate with 99mTc-DTPA. Eur J Nucl Med 11:7–12CrossRefPubMed
go back to reference Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF (1996) Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14:1504–1511PubMed Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF (1996) Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14:1504–1511PubMed
go back to reference Gates GF (1985) Creatinine clearance estimation from serum creatinine values: an analysis of three mathematical models of glomerular function. Am J Kidney Dis 5:199–205PubMed Gates GF (1985) Creatinine clearance estimation from serum creatinine values: an analysis of three mathematical models of glomerular function. Am J Kidney Dis 5:199–205PubMed
go back to reference Gutman Y, Gottschalk CW, Lassiter WE (1965) Micropuncture study of inulin absorption in the rat kidney. Science 147:753–754PubMedCrossRef Gutman Y, Gottschalk CW, Lassiter WE (1965) Micropuncture study of inulin absorption in the rat kidney. Science 147:753–754PubMedCrossRef
go back to reference Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD (1986) Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17:277–280CrossRefPubMed Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD (1986) Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17:277–280CrossRefPubMed
go back to reference Hoffmann A, Nimtz M, Conradt HS (1997) Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 7:499–506PubMedCrossRef Hoffmann A, Nimtz M, Conradt HS (1997) Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 7:499–506PubMedCrossRef
go back to reference Hull JH, Hak LJ, Koch GG, Wargin WA, Chi SL, Mattocks AM (1981) Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther 29:516–521PubMedCrossRef Hull JH, Hak LJ, Koch GG, Wargin WA, Chi SL, Mattocks AM (1981) Influence of range of renal function and liver disease on predictability of creatinine clearance. Clin Pharmacol Ther 29:516–521PubMedCrossRef
go back to reference Jacobsson B, Lignelid H, Bergerheim US (1995) Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 26:559–564PubMedCrossRef Jacobsson B, Lignelid H, Bergerheim US (1995) Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 26:559–564PubMedCrossRef
go back to reference Jelliffe RW (1971) Estimation of creatinine clearance when urine cannot be collected. Lancet 1:975–976CrossRefPubMed Jelliffe RW (1971) Estimation of creatinine clearance when urine cannot be collected. Lancet 1:975–976CrossRefPubMed
go back to reference Jelliffe RW (1973) Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604–605PubMed Jelliffe RW (1973) Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604–605PubMed
go back to reference Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528PubMed Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528PubMed
go back to reference Kos J, Stabuc B, Cimerman N, Brunner N (1998) Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44:2556–2557PubMed Kos J, Stabuc B, Cimerman N, Brunner N (1998) Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44:2556–2557PubMed
go back to reference Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A (1994) Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40:1921–1926PubMed Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A (1994) Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40:1921–1926PubMed
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed
go back to reference Lewis R, Kerr N, Van Buren C, Lowry P, Sandler C, Frazier OH, Powers P, Herson J, Corriere J, Jr, Kerman R, (1989) Comparative evaluation of urographic contrast media, inulin, and 99mTc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation. Transplantation 48:790–796PubMedCrossRef Lewis R, Kerr N, Van Buren C, Lowry P, Sandler C, Frazier OH, Powers P, Herson J, Corriere J, Jr, Kerman R, (1989) Comparative evaluation of urographic contrast media, inulin, and 99mTc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation. Transplantation 48:790–796PubMedCrossRef
go back to reference Lipp HP, Bokemeyer C (1999) Clinical pharmacokinetics of cytostatic drugs: efficacy and toxicity. In: Lipp HP (ed) Anticancer drug toxicity. Dekker, New York, pp 11–201 Lipp HP, Bokemeyer C (1999) Clinical pharmacokinetics of cytostatic drugs: efficacy and toxicity. In: Lipp HP (ed) Anticancer drug toxicity. Dekker, New York, pp 11–201
go back to reference Martin L, Chatelut E, Boneu A, Rostaing L, Roussilhes C, Caselles O, Canal P (1998) Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer 85:631–636PubMed Martin L, Chatelut E, Boneu A, Rostaing L, Roussilhes C, Caselles O, Canal P (1998) Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer 85:631–636PubMed
go back to reference Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG (2004) Evaluation of the Cockcroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291–295CrossRefPubMed Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG (2004) Evaluation of the Cockcroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291–295CrossRefPubMed
go back to reference Mawer GE, Lucas SB, Knowles BR, Stirland RM (1972) Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1:12–15CrossRefPubMed Mawer GE, Lucas SB, Knowles BR, Stirland RM (1972) Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet 1:12–15CrossRefPubMed
go back to reference Melegos DN, Grass L, Pierratos A, Diamandis EP (1999) Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. Urology 53:32–37CrossRefPubMed Melegos DN, Grass L, Pierratos A, Diamandis EP (1999) Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. Urology 53:32–37CrossRefPubMed
go back to reference Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R (1996) Carboplatin dosing based on measurement of renal function–experience at the Peter MacCallum Cancer Institute. Aust NZJ Med 26:372–379 Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R (1996) Carboplatin dosing based on measurement of renal function–experience at the Peter MacCallum Cancer Institute. Aust NZJ Med 26:372–379
go back to reference Montgomery MJ, Beringer PM, Louie SG, Gill MA (2000) Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit 22:695–700CrossRefPubMed Montgomery MJ, Beringer PM, Louie SG, Gill MA (2000) Estimation of creatinine clearance in patients with metastatic ovarian cancer. Ther Drug Monit 22:695–700CrossRefPubMed
go back to reference Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP (1995) Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47:312–318PubMedCrossRef Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP (1995) Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47:312–318PubMedCrossRef
go back to reference O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91–96CrossRefPubMed O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91–96CrossRefPubMed
go back to reference Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953PubMed Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953PubMed
go back to reference Poole SG, Dooley MJ, Rischin D (2002) A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 13:949–955CrossRefPubMed Poole SG, Dooley MJ, Rischin D (2002) A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 13:949–955CrossRefPubMed
go back to reference Price CP, Finney H (2000) Developments in the assessment of glomerular filtration rate. Clin Chim Acta 297:55–66CrossRefPubMed Price CP, Finney H (2000) Developments in the assessment of glomerular filtration rate. Clin Chim Acta 297:55–66CrossRefPubMed
go back to reference Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K (1999) Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 45:567–568PubMed Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K (1999) Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 45:567–568PubMed
go back to reference Priem F, Althaus H, Jung K, Sinha P (2001) Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. Clin Chem 47:2181PubMed Priem F, Althaus H, Jung K, Sinha P (2001) Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. Clin Chem 47:2181PubMed
go back to reference Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304–309PubMed Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304–309PubMed
go back to reference Rehling M, Moller ML, Thamdrup B, Lund JO, Trap-Jensen J (1984) Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci (Lond) 66:613–619 Rehling M, Moller ML, Thamdrup B, Lund JO, Trap-Jensen J (1984) Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci (Lond) 66:613–619
go back to reference Robinson BA, Frampton CM, Colls BM, Atkinson CH, Fitzharris BM (1990) Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate. Aust NZJ Med 20:657–662 Robinson BA, Frampton CM, Colls BM, Atkinson CH, Fitzharris BM (1990) Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate. Aust NZJ Med 20:657–662
go back to reference Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84:1053–1060CrossRefPubMed Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84:1053–1060CrossRefPubMed
go back to reference Smyth JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG (1980) The clinical pharmacology of the adenosine deaminase inhibitor 2’-deoxycoformycin. Cancer Chemother Pharmacol 5:93–101CrossRefPubMed Smyth JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG (1980) The clinical pharmacology of the adenosine deaminase inhibitor 2’-deoxycoformycin. Cancer Chemother Pharmacol 5:93–101CrossRefPubMed
go back to reference Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB (1994) Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946–1954PubMed Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB (1994) Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946–1954PubMed
go back to reference Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, Asano Y (1997) Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol 48:104–108PubMed Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, Asano Y (1997) Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol 48:104–108PubMed
go back to reference Tsubaki T, Goodin S, Leader WG, Chandler MH (1993) Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 12:685–690PubMed Tsubaki T, Goodin S, Leader WG, Chandler MH (1993) Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 12:685–690PubMed
go back to reference Wan SH, Huffman DH, Azarnoff DL, Hoogstraten B, Larsen WE (1974) Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res 34:392–397PubMed Wan SH, Huffman DH, Azarnoff DL, Hoogstraten B, Larsen WE (1974) Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res 34:392–397PubMed
go back to reference Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452–459CrossRefPubMed Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452–459CrossRefPubMed
Metadata
Title
Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge
Authors
Karin Holweger
Carsten Bokemeyer
Hans-Peter Lipp
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-005-0679-7

Other articles of this Issue 9/2005

Journal of Cancer Research and Clinical Oncology 9/2005 Go to the issue